Working Towards Better Drug Delivery Systems for Chemotherapeutics

A recent investigation by CMRI’s Peptide Facility Lead, Dr. Md Musfizur Hassan (1st author) and his collaborators at University of New South Wales and University of South Australia, explored the use of liposome-micelle-hybrid (LMH) carriers to enhance the delivery of the clinically relevant chemotherapeutics Paclitaxel (PTX) and 5-fluorouracil (5-FU).  It has well been established that these drugs are either of low solubility or permeability with a limited controlled release from nanocarriers resulting in a reduction in treatment efficacy. 

Their recent research article, titled Liposome-Micelle-Hybrid (LMH) Carriers for Controlled Co-Delivery of 5-FU and Paclitaxel as Chemotherapeutics published in the Pharmaceutics: Special Edition of Advanced Liposomes for Drug Delivery, found that using an optimised combination of liposomes and micelles can enhance pharmacological performance and chemotherapeutic potential of PTX and 5_FU with increased drug loading, improved solubility, and transport/permeability.

Read the full article here: https://www.mdpi.com/1999-4923/15/7/1886

For more information about this publication, or on the capabilities, applications, and services provided by CMRI’s Peptide Synthesis Facility, please contact  Dr Md Musfizur Hassan via email: amides@cmri.org.au.